Diana Isaacs1, Lalita Prasad-Reddy2, Sneha Baxi Srivastava3. 1. Chicago State University, Chicago, ILOak Lawn VA Clinic of Edward Hines Jr. VA Hospital, Oak Lawn, IL. dianamisaacs@gmail.com. 2. Chicago State University, Chicago, ILRush University Medical Center, Chicago, IL. 3. Chicago State University, Chicago, ILACCESS Community Health Network, Chicago, IL.
Abstract
PURPOSE: Published data on the weight loss effects of glucagon-like peptide 1 (GLP-1) receptor agonists are reviewed, with a focus on data from clinical trials. SUMMARY: Obesity is a significant health problem in the United States (an estimated 69% of U.S. adults are overweight and nearly 35% are obese), and few drugs have proven safety and efficacy as adjuncts to lifestyle modification for weight management. GLP-1 receptor agonists are used for glycemic control in patients with type 2 diabetes and have been studied for their weight loss effects in patients with and without diabetes; these agents produce weight loss benefits through their effects on satiety and gastric emptying. In December 2014, the liraglutide product Saxenda (Novo Nordisk) became the first GLP-1 receptor agonist approved by the Food and Drug Administration (FDA) for use in long-term weight management. Results of clinical trials that evaluated the effects of GLP-1 receptor agonist therapy on weight and body mass index indicated outcomes comparable or superior to those achieved with the use of other antiobesity agents. As a class, GLP-1 receptor agonists have a generally more favorable safety profile than several other antiobesity agents; transient, mild-to-moderate gastrointestinal symptoms were the most frequently reported adverse effects in clinical trials. CONCLUSION: Originally marketed for glycemic control in type 2 diabetes, GLP-1 receptor agonists have been found effective for weight reduction in patients with and without type 2 diabetes. Liraglutide is currently the only GLP-1 receptor agonist approved by FDA for obesity treatment.
PURPOSE: Published data on the weight loss effects of glucagon-like peptide 1 (GLP-1) receptor agonists are reviewed, with a focus on data from clinical trials. SUMMARY:Obesity is a significant health problem in the United States (an estimated 69% of U.S. adults are overweight and nearly 35% are obese), and few drugs have proven safety and efficacy as adjuncts to lifestyle modification for weight management. GLP-1 receptor agonists are used for glycemic control in patients with type 2 diabetes and have been studied for their weight loss effects in patients with and without diabetes; these agents produce weight loss benefits through their effects on satiety and gastric emptying. In December 2014, the liraglutide product Saxenda (Novo Nordisk) became the first GLP-1 receptor agonist approved by the Food and Drug Administration (FDA) for use in long-term weight management. Results of clinical trials that evaluated the effects of GLP-1 receptor agonist therapy on weight and body mass index indicated outcomes comparable or superior to those achieved with the use of other antiobesity agents. As a class, GLP-1 receptor agonists have a generally more favorable safety profile than several other antiobesity agents; transient, mild-to-moderate gastrointestinal symptoms were the most frequently reported adverse effects in clinical trials. CONCLUSION: Originally marketed for glycemic control in type 2 diabetes, GLP-1 receptor agonists have been found effective for weight reduction in patients with and without type 2 diabetes. Liraglutide is currently the only GLP-1 receptor agonist approved by FDA for obesity treatment.
Authors: Sofia Dahlqvist; Elsa Ahlén; Karin Filipsson; Thomas Gustafsson; Irl B Hirsch; Jaakko Tuomilehto; Henrik Imberg; Bo Ahrén; Stig Attvall; Marcus Lind Journal: BMJ Open Diabetes Res Care Date: 2018-02-24
Authors: S S Ahmadi; K Filipsson; H Dimenäs; S S Isaksson; H Imberg; S Sjöberg; B Ahrén; S Dahlqvist; T Gustafsson; J Tuomilehto; I B Hirsch; M Lind Journal: Obes Sci Pract Date: 2019-03-18
Authors: Mathias E Jensen; Aurelio Galli; Morgane Thomsen; Kathrine L Jensen; Gerda K Thomsen; Mette K Klausen; Tina Vilsbøll; Mikkel B Christensen; Jens J Holst; Anthony Owens; Sabrina Robertson; Lynette Daws; Daniele Zanella; Ulrik Gether; Gitte M Knudsen; Anders Fink-Jensen Journal: Neurochem Int Date: 2020-05-25 Impact factor: 3.921